K
95.03
4.35 (4.80%)
| Penutupan Terdahulu | 90.68 |
| Buka | 86.00 |
| Jumlah Dagangan | 1,246,269 |
| Purata Dagangan (3B) | 992,155 |
| Modal Pasaran | 7,602,307,072 |
| Harga / Jualan (P/S) | 182.36 |
| Harga / Buku (P/B) | 4.37 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Feb 2026 |
| Margin Operasi (TTM) | -336.77% |
| EPS Cair (TTM) | -3.11 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 114.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 10.98% |
| Nisbah Semasa (MRQ) | 8.49 |
| Aliran Tunai Operasi (OCF TTM) | -234.06 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -136.32 M |
| Pulangan Atas Aset (ROA TTM) | -19.47% |
| Pulangan Atas Ekuiti (ROE TTM) | -32.17% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Kymera Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
-1.0
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | -4.0 |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 0.5 |
| Purata | -1.00 |
|
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients’ lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.50% |
| % Dimiliki oleh Institusi | 104.98% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 140.00 (Piper Sandler, 47.32%) | Beli |
| Median | 124.00 (30.49%) | |
| Rendah | 100.00 (Stephens & Co., 5.23%) | Beli |
| Purata | 121.88 (28.25%) | |
| Jumlah | 8 Beli | |
| Harga Purata @ Panggilan | 87.04 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| UBS | 03 Mar 2026 | 128.00 (34.69%) | Beli | 86.35 |
| Citigroup | 02 Mar 2026 | 120.00 (26.28%) | Beli | 90.10 |
| Stephens & Co. | 02 Mar 2026 | 100.00 (5.23%) | Beli | 90.10 |
| BTIG | 26 Feb 2026 | 134.00 (41.01%) | Beli | 95.03 |
| 03 Feb 2026 | 138.00 (45.22%) | Beli | 77.22 | |
| Piper Sandler | 26 Feb 2026 | 140.00 (47.32%) | Beli | 95.03 |
| Barclays | 28 Jan 2026 | 133.00 (39.96%) | Beli | 71.16 |
| B. Riley Securities | 22 Dec 2025 | 117.00 (23.12%) | Beli | 84.35 |
| RBC Capital | 16 Dec 2025 | 103.00 (8.39%) | Beli | 84.19 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| ADAMS BRIAN | 90.10 | - | 4,125 | 371,663 |
| BOOTH BRUCE | - | 90.10 | -81,866 | -7,376,127 |
| CHADWICK JEREMY G | 90.10 | 88.11 | 6,617 | 611,829 |
| GOLLOB JARED | 90.10 | 88.11 | 7,142 | 663,025 |
| GOODMAN NOAH | 90.10 | - | 9,225 | 831,173 |
| JACOBS BRUCE N. | 90.10 | 88.11 | 5,179 | 486,159 |
| Jumlah Keseluruhan Kuantiti Bersih | -49,578 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -4,412,279 | |||
| Purata Pembelian Keseluruhan ($) | 90.10 | |||
| Purata Jualan Keseluruhan ($) | 88.39 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| JACOBS BRUCE N. | Pegawai | 04 Mar 2026 | Jual (-) | 4,895 | 86.11 | 421,508 |
| GOLLOB JARED | Pegawai | 04 Mar 2026 | Jual (-) | 4,895 | 86.11 | 421,508 |
| CHADWICK JEREMY G | Pegawai | 04 Mar 2026 | Jual (-) | 3,919 | 86.11 | 337,465 |
| BOOTH BRUCE | Pengarah | 02 Mar 2026 | Jual automatik (-) | 81,866 | 90.10 | 7,376,127 |
| ADAMS BRIAN | Pegawai | 02 Mar 2026 | Diperolehi (+) | 4,125 | 90.10 | 371,663 |
| JACOBS BRUCE N. | Pegawai | 02 Mar 2026 | Diperolehi (+) | 17,650 | 90.10 | 1,590,265 |
| JACOBS BRUCE N. | Pegawai | 02 Mar 2026 | Jual (-) | 7,576 | 90.10 | 682,598 |
| GOLLOB JARED | Pegawai | 02 Mar 2026 | Diperolehi (+) | 17,650 | 90.10 | 1,590,265 |
| GOLLOB JARED | Pegawai | 02 Mar 2026 | Jual (-) | 5,613 | 90.10 | 505,731 |
| GOODMAN NOAH | Pegawai | 02 Mar 2026 | Diperolehi (+) | 9,225 | 90.10 | 831,173 |
| CHADWICK JEREMY G | Pegawai | 02 Mar 2026 | Diperolehi (+) | 12,575 | 90.10 | 1,133,008 |
| CHADWICK JEREMY G | Pegawai | 02 Mar 2026 | Jual (-) | 2,039 | 90.10 | 183,714 |
| Papar semua | ||||||
| Tarikh | Jenis | Butiran |
|---|---|---|
| 04 Feb 2026 | Pengumuman | Kymera Therapeutics to Participate in Upcoming February Investor Conferences |
| 29 Jan 2026 | Pengumuman | Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader |
| 13 Jan 2026 | Pengumuman | Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs |
| 06 Jan 2026 | Pengumuman | Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |